PBR Nachrichten

 

The Prescription Drug User Fee Act (PDUFA) date for trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate (ADC) and potential new medicine for the treatment of HER2-positive metastatic breast The post Trastuzumab deruxtecan granted FDA pr...

Horizon Therapeutics has initiated an open-label clinical trial evaluating the use of KRYSTEXXA (pegloticase injection) in adults with chronic gout refractory to conventional therapies - also known as The post Horizon Therapeutics initiates PROTECT ...

The FDA has approved the company's supplemental new drug application (sNDA) for Xofluza to treat acute, uncomplicated influenza, or flu, in people 12 years of age and older The post FDA approves Roche's Xofluza for patients at high risk of develop...

The trial will investigate how different doses of the compound, an inhaled epithelial sodium channel (ENaC) inhibitor, impact lung function compared to placebo when added to the standard The post Boehringer Ingelheim enrols first patient in Phase II...

The center of excellence specializes in injectable pharmaceutical capabilities including flexible manufacturing solutions for liquid and lyophilized products. The facility, located at 627 Davis Drive in Morrisville and The post TriPharm Services ann...

Achillion is involved in the development of oral small molecule Factor D inhibitors for the treatment of people with complement alternative pathway-mediated rare diseases such as paroxysmal nocturnal The post Alexion to buy clinical-stage biopharmac...

The agreement allows CRISPR, a Swiss gene editing company, to gain access to the KSQ Therapeutics' intellectual property (IP) for editing certain gene targets in its allogeneic oncology The post CRISPR, KSQ Therapeutics join forces to advance cell ...

"This partnership will significantly widen Trialbee's service offerings to drive patient recruitment and retention,� said Lollo Eriksson, CEO of Trialbee. "This is a great opportunity to leverage both The post Trialbee and TriNetX partner to accele...

Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor (SNRI) designed for the treatment of various neuro-psychiatric and pain disorders in patients who have difficulty swallowing - a The post Sun Pharma launches Drizalma Sprinkle in...

The divestment is part of Takeda's strategy to focus on core business areas and facilitate rapid deleveraging following its acquisition of Shire. Takeda growth and emerging markets business The post Acino to buy Takeda’s select OTC and prescr...

According to the life sciences company, the technology used by the IonicX XRF Analyzer helps save time and money that is otherwise used on conventional analysis techniques. This The post Thermo Fisher launches IonicX XRF Analyzer to identity ionic s...

Over time, patients taking levodopa may begin to experience periods when PD symptoms, including motor fluctuations, re-emerge between treatment doses. These are called "off� episodes. "We are pleased The post Kyowa Kirin launches NOURIANZ in US for ...

Simultaneously, the company completed a Series C financing led by HBM Partners with participation from new and existing investors. AVID200 is rationally designed to selectively and potently inhibit The post Forbius completes enrollment into phase 1a...

The approval has been granted for Xarelto to prevent venous thromboembolism (VTE) or blood clots in hospitalised acutely ill medical patients at risk for thromboembolic complications who are The post Janssen, Bayer get FDA nod for Xarelto to prevent...

The PEMPHIX trial also showed that MabThera was superior to mycophenolate mofetil (MMF) in the late-stage trial held in adult patients. PEMPHIX has been taken up by Roche The post MabThera meets primary endpoint in PEMPHIX trial in pemphigus vulgari...

Abrocitinib, an investigational oral Janus kinase 1 (JAK1) inhibitor, met all the co-primary and key secondary endpoints, which were related to skin clearance and itch relief compared to The post Pfizer presents positive phase 3 data for abrocitinib...

CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.S. Food and Drug Administration (FDA), is indicated to increase tear production in patients The post Sun Pharma launches CEQUA for treatment of dry ey...

Reyvow is a new oral medication for the acute treatment of migraine, with or without aura, in adults. It binds to 5-HT1F receptors with high affinity. Reyvow is The post Eli Lilly gets FDA approval for migraine drug Reyvow appeared first on Pharmace...

"We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,� said John Sundy, MD, PhD, Senior Vice President, Inflammation The post Gilead, Galapagos announce 52-week results of filgotinib in FI...

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced The post Belgium's UCB to buy Ra Pharmaceuticals for $ 2.1bn appeared first on...